forex signal system trading: Biotech opportunity: Could go from $0 to $80 billion by 2021

You are receiving this as a part of your subscription to The Startup Investor. To remove your email from this list, unsubscribe here.

Dear Startup Investor,

The race for a COVID-19 vaccine is in full swing.

Over 70 firms are working night and day to develop a viable vaccine for the public.

And when that happens, one thing is clear...

This vaccine could be the most profitable drug in history.

I'm not just saying that - this statement comes directly from the New York Times.

And according to our projections, we expect a vaccine to be worth $80 billion in revenue by as early as 2021.

So this is CLEARLY a big opportunity for investors.

There's only one problem...

Most people have no idea...

WHICH company is pulling ahead in this race...
WHOSE vaccine will likely reach the market first, or...
HOW long it could take to arrive in your town.

Well, we have the answers.

Not only do we know one company is leading the pack...

But we actually hunted down the CEO of this firm...

And, in between his clinical trials, we recorded an exclusive interview with him.

That's how we got our hands on a nugget of information that could be INCREDIBLY lucrative:

This company is expected to release clinical trial results by June 30!

And the minute that happens, their shares could soar like a rocket.

In total, our projections show this event could spark a 3,000% stock surge.

That's why if you want to learn how to get in on the best investment of the year, decade, maybe even century...

You NEED to watch this video now.

Any biotech stock that even mentions the word vaccine is going absolutely haywire.

So what do you think is going to happen when one of them comes up with a PROVEN vaccine for COVID-19?

You'll get the full rundown in this presentation.

Here's to your success,

Bob Keppel
Publisher, The Startup Investor

Please do not reply to this email. It was sent from an unmonitored mailbox.

You are receiving this e-mail at phanphuongthanh89.822152@blogger.com, as part of your subscription to The Startup Investor. To remove your email from this list: unsubscribe here.

To cancel, or for any other questions or requests, please contact our Customer Service team:
Online
Phone: 866-310-1498 (North America) 410-501-5876 (International)
Mail: The Startup Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201
Our Customer Service team is available Monday ‑ Friday between 9:00 AM and 5:00 PM ET.

© 2020 Angels & Entrepreneurs. All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Angels & Entrepreneurs. 1125 N Charles Street, Baltimore, MD 21201.

Website | Privacy Policy | Terms & Conditions

Biotech opportunity: Could go from $0 to $80 billion by 2021

No comments:

Post a Comment